Kamada (KMDA) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a buy rating in a report published on Thursday, Zacks.com reports. Zacks Investment Research currently has $6.75 price objective on the biotechnology company’s stock.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

A number of other analysts have also commented on KMDA. ValuEngine raised shares of Kamada from a sell rating to a hold rating in a report on Thursday, December 20th. HC Wainwright reaffirmed a buy rating and set a $11.00 target price on shares of Kamada in a report on Thursday, February 14th.

KMDA opened at $6.17 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.70 and a quick ratio of 3.46. Kamada has a 52 week low of $4.50 and a 52 week high of $6.70. The firm has a market cap of $248.42 million, a price-to-earnings ratio of 11.22 and a beta of 1.16.

Kamada (NASDAQ:KMDA) last released its earnings results on Tuesday, February 12th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.29. Kamada had a net margin of 19.48% and a return on equity of 22.74%. The firm had revenue of $48.21 million during the quarter. Equities analysts expect that Kamada will post 0.47 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Kamada by 17.9% in the 3rd quarter. Renaissance Technologies LLC now owns 548,100 shares of the biotechnology company’s stock valued at $3,398,000 after buying an additional 83,200 shares during the period. Vanguard Group Inc. raised its holdings in Kamada by 11.6% during the third quarter. Vanguard Group Inc. now owns 583,797 shares of the biotechnology company’s stock worth $3,620,000 after purchasing an additional 60,866 shares during the last quarter. Vanguard Group Inc raised its holdings in Kamada by 11.6% during the third quarter. Vanguard Group Inc now owns 583,797 shares of the biotechnology company’s stock worth $3,620,000 after purchasing an additional 60,866 shares during the last quarter. ETF Managers Group LLC acquired a new position in Kamada during the fourth quarter worth $263,000. Finally, Ramsey Quantitative Systems raised its holdings in Kamada by 341.7% during the fourth quarter. Ramsey Quantitative Systems now owns 36,154 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 27,969 shares during the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

Read More: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.